Does the media refer more to AMGN or REGN?

In the previous week, Regeneron Pharmaceuticals had 1 more articles in the media than Amgen. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 25 mentions for Amgen. Amgen's average media sentiment score of 0.67 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 12 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Regeneron Pharmaceuticals 8 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GILD or REGN?

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Gilead Sciences. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 12 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.88 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 8 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRNA or REGN?

In the previous week, Moderna had 15 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 41 mentions for Moderna and 26 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.61 beat Moderna's score of 0.33 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 16 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 8 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor REGN or NTLA?

In the previous week, Regeneron Pharmaceuticals had 24 more articles in the media than Intellia Therapeutics. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.83 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 8 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to REGN or VIR?

In the previous week, Regeneron Pharmaceuticals had 22 more articles in the media than Vir Biotechnology. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 4 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.81 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 8 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Regeneron Pharmaceuticals (REGN) Competitors

$750.51 -1.74 (-0.23%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$758.02 +7.51 (+1.00%)

As of 09/29/2026 07:56 PM Eastern

Compare

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you buy Regeneron Pharmaceuticals stock or one of its competitors? Regeneron Pharmaceuticals's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Regeneron Pharmaceuticals compare to Amgen?

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Amgen has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Amgen pays out 62.6% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Regeneron Pharmaceuticals had 1 more articles in the media than Amgen. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 25 mentions for Amgen. Amgen's average media sentiment score of 0.67 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	12 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	8 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	6.23	$7.71B	$16.09	26.33
Regeneron Pharmaceuticals	$14.34B	5.39	$4.50B	$40.46	18.55

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Amgen presently has a consensus price target of $385.25, suggesting a potential downside of 9.06%. Regeneron Pharmaceuticals has a consensus price target of $802.18, suggesting a potential upside of 6.88%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Amgen beats Regeneron Pharmaceuticals on 11 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Gilead Sciences. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 12 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.88 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	8 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gilead Sciences currently has a consensus price target of $158.78, indicating a potential upside of 4.96%. Regeneron Pharmaceuticals has a consensus price target of $802.18, indicating a potential upside of 6.88%. Given Regeneron Pharmaceuticals' higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.37	$8.51B	-$2.67	N/A
Regeneron Pharmaceuticals	$14.34B	5.39	$4.50B	$40.46	18.55

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 12 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	41.78	-$2.82B	-$7.99	N/A
Regeneron Pharmaceuticals	$14.34B	5.39	$4.50B	$40.46	18.55

Moderna has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Moderna presently has a consensus target price of $76.72, suggesting a potential downside of 62.29%. Regeneron Pharmaceuticals has a consensus target price of $802.18, suggesting a potential upside of 6.88%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	14 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.12
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Moderna had 15 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 41 mentions for Moderna and 26 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.61 beat Moderna's score of 0.33 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	16 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	8 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Moderna shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Regeneron Pharmaceuticals currently has a consensus target price of $802.18, indicating a potential upside of 6.88%. Intellia Therapeutics has a consensus target price of $20.98, indicating a potential upside of 74.38%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Intellia Therapeutics' net margin of -672.16%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

In the previous week, Regeneron Pharmaceuticals had 24 more articles in the media than Intellia Therapeutics. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.83 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	8 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.39	$4.50B	$40.46	18.55
Intellia Therapeutics	$59.51M	28.33	-$412.69M	-$3.36	N/A

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Vir Biotechnology's net margin of -638.88%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

In the previous week, Regeneron Pharmaceuticals had 22 more articles in the media than Vir Biotechnology. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 4 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.81 beat Regeneron Pharmaceuticals' score of 0.61 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	8 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.39	$4.50B	$40.46	18.55
Vir Biotechnology	$68.56M	26.29	-$437.99M	-$1.86	N/A

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Regeneron Pharmaceuticals presently has a consensus price target of $802.18, indicating a potential upside of 6.88%. Vir Biotechnology has a consensus price target of $21.57, indicating a potential upside of 102.55%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$77.45B	$3.96B	$7.34B	$13.05B
Dividend Yield	0.50%	3.63%	2.52%	14.18%
P/E Ratio	18.55	13.66	273.79	25.68
Price / Sales	5.39	1,346.82	626.32	85.12
Price / Cash	17.92	121.91	80.06	52.35
Price / Book	2.54	15.28	10.44	6.34
Net Income	$4.50B	-$22.71M	$3.50B	$360.56M
7 Day Performance	-6.40%	-2.05%	-1.41%	-1.59%
1 Month Performance	-5.50%	-8.36%	-4.17%	-4.08%
1 Year Performance	33.48%	26.25%	12.60%	3.79%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	3.9357 of 5 stars	$750.51 -0.2%	$802.18 +6.9%	+33.8%	$77.45B	$14.34B	18.55	15,410	Trending News Analyst Forecast
AMGN Amgen	3.4029 of 5 stars	$406.09 -1.0%	$383.46 -5.6%	+54.6%	$219.54B	$36.75B	25.24	31,500	Analyst Forecast
GILD Gilead Sciences	4.0253 of 5 stars	$151.37 -0.9%	$158.78 +4.9%	+34.3%	$187.69B	$29.44B	N/A	17,000
MRNA Moderna	1.9781 of 5 stars	$182.11 -0.2%	$76.72 -57.9%	+703.2%	$72.71B	$1.94B	N/A	4,700
NTLA Intellia Therapeutics	3.0472 of 5 stars	$12.33 -2.8%	$20.98 +70.1%	-28.9%	$1.73B	$67.67M	N/A	377

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Which has more risk and volatility, AMGN or REGN?

Is AMGN or REGN more profitable?

Is AMGN or REGN a better dividend stock?

Does the media refer more to AMGN or REGN?

Which has better valuation and earnings, AMGN or REGN?

Do insiders & institutionals hold more shares of AMGN or REGN?

Do analysts prefer AMGN or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Is GILD or REGN more profitable?

Is GILD or REGN a better dividend stock?

Which has more risk and volatility, GILD or REGN?

Does the media prefer GILD or REGN?

Do institutionals and insiders hold more shares of GILD or REGN?

Do analysts rate GILD or REGN?

Which has higher valuation and earnings, GILD or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Which has stronger valuation and earnings, MRNA or REGN?

Which has more risk and volatility, MRNA or REGN?

Is MRNA or REGN more profitable?

Do analysts recommend MRNA or REGN?

Does the media favor MRNA or REGN?

Do institutionals & insiders have more ownership in MRNA or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Do analysts prefer REGN or NTLA?

Is REGN or NTLA more profitable?

Does the media favor REGN or NTLA?

Which has higher valuation and earnings, REGN or NTLA?

Do institutionals and insiders believe in REGN or NTLA?

Which has more risk & volatility, REGN or NTLA?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Do institutionals & insiders believe in REGN or VIR?

Is REGN or VIR more profitable?

Does the media refer more to REGN or VIR?

Which has preferable earnings & valuation, REGN or VIR?

Which has more volatility & risk, REGN or VIR?

Do analysts prefer REGN or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools